{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:30:46Z","timestamp":1792643446155,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The continuation of anti-vascular endothelial growth factor (anti-VEGF) treatment after achieving stability in patients with neovascular age-related macular degeneration has generally been advocated. In our own patients, we thought to assess whether continued anti-VEGF treatment is capable of preventing recurrences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational case series, patients with stable disease either opted to continue treatment every 12\u201314 weeks (Group 1) or stopped treatment with subsequent follow-up visits every 8\u201312 weeks (Group 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 103 eyes of 103 patients achieving stability, 49 eyes continued treatment (Group 1), whereas treatment was stopped in 54 eyes undergoing regular follow-up (Group 2). Recurrent disease was observed in 21 (42.9%) and 33 (61.1%) cases in Group 1 and Group 2, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). Time between achieving stable disease and recurrence was comparable between Group 1 and Group 2 (11.1\u2009\u00b1\u20098.2 months vs. 9.2\u2009\u00b1\u20096.7 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.43). The number of visits between achieving stability and disease recurrence was similar, but not the number of injections (3.5\u2009\u00b1\u20092.0 vs. 0.2\u2009\u00b1\u20090.4;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Continuing anti-VEGF therapy after achieving functional and morphological stability every 12\u201314 weeks does not prevent recurrences. Patients deserve to be informed of a potential lifetime risk of recurrences, even under continued therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-021-01562-6","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:03:29Z","timestamp":1620039809000},"page":"862-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Traine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Wons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-8390","authenticated-orcid":false,"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1562_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY. et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1419\u201331.","journal-title":"N. Engl J Med"},{"key":"1562_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY. et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1432\u201344.","journal-title":"N. Engl J Med"},{"key":"1562_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","volume":"150","author":"P Abraham","year":"2010","unstructured":"Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150:315\u2013324.e1.","journal-title":"Am J Ophthalmol"},{"key":"1562_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.01.059","volume":"120","author":"JS Heier","year":"2013","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2013;120:209\u201310.","journal-title":"Ophthalmology"},{"key":"1562_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW Trials. Ophthalmology. 2016;123:1521\u20139.","journal-title":"Ophthalmology"},{"key":"1562_CR6","doi-asserted-by":"publisher","first-page":"2181e2192.","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181e2192.","journal-title":"Ophthalmology"},{"key":"1562_CR7","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"1562_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","volume":"1","author":"PK Kaiser","year":"2017","unstructured":"Kaiser PK, Singer M, Tolentino M, Vitti R, Erickson K, Saroj N, et al. Long-term safety and visual outcome of intravitreal aflibercept in neovascular age-related macular degeneration: VIEW 1 Extension Study. Ophthalmol Retin. 2017;1:304\u201313.","journal-title":"Ophthalmol Retin"},{"key":"1562_CR9","doi-asserted-by":"publisher","first-page":"2497e2503","DOI":"10.1016\/j.ophtha.2015.08.014","volume":"122","author":"G Richard","year":"2015","unstructured":"Richard G, Mones J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497e2503.","journal-title":"Ophthalmology"},{"key":"1562_CR10","doi-asserted-by":"publisher","first-page":"51e59","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study treat-and extend protocol: two-year results. Ophthalmology. 2016;123:51e59.","journal-title":"Ophthalmology"},{"key":"1562_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"1562_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29:721\u201331.","journal-title":"Eye"},{"key":"1562_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","volume":"3","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex RW, Barthelmes D, et al. Fight Retinal Blindness! Study Group. Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months. Ophthalmol Retin. 2019;3:623\u20138.","journal-title":"Ophthalmol Retin"},{"key":"1562_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","volume":"39","author":"P Arendt","year":"2019","unstructured":"Arendt P, Yu S, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Exit strategy in a treat and extend regime for exudative age related macular degeneration. Retina. 2019;39:27\u201333.","journal-title":"Retina"},{"key":"1562_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.oret.2019.04.013","volume":"3","author":"RN Khurana","year":"2019","unstructured":"Khurana RN. Long-term management of neovascular age-related macular degeneration: to suspend or not to suspend? Ophthalmol Retin. 2019;3:621\u20132.","journal-title":"Ophthalmol Retin"},{"key":"1562_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30:1046\u201350.","journal-title":"Retina"},{"key":"1562_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0253-7176.116232","volume":"35","author":"J Charan","year":"2013","unstructured":"Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35:121\u20136.","journal-title":"Indian J Psychol Med"},{"key":"1562_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.oret.2017.10.002","volume":"2","author":"EA Lowry","year":"2018","unstructured":"Lowry EA, Nguyen V, Daien V, Barthelmes D, Gillies MC. Outcomes in neovascular age-related macular degeneration when neovascular lesion activity is uncertain: observational study. Ophthalmol Retin. 2018;2:531\u20138.","journal-title":"Ophthalmol Retin"},{"key":"1562_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2019.06.017","volume":"208","author":"J Yang","year":"2019","unstructured":"Yang J, Zhang Q, Motulsky EH, Thulliez M, Shi Y, Lyu C, et al. Two-year risk of exudation in eyes with non-exudative AMD and subclinical neovascularization detected with swept source OCT angiography. Am J Ophthalmol. 2019;208:1\u201311.","journal-title":"Am J Ophthalmol"},{"key":"1562_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1167\/iovs.16-20977","volume":"58","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Chen CL, Chu Z, Zheng F, Miller A, Roisman L, et al. Automated quantitation of choroidal neovascularization: A comparison study between spectral-domain and swept-source OCT angiograms. Investig Ophthalmol Vis Sci. 2017;58:1506\u201313.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1562_CR22","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1167\/iovs.16-20969","volume":"58","author":"AR Miller","year":"2017","unstructured":"Miller AR, Roisman L, Zhang Q, Zheng F, de Olivera Dias JR, Yehoshua Z, et al. Comparison between spectral-domain and swept-source optical coherence tomography angiographic imaging of choroidal neovascularization. Investig Ophthalmol Vis Sci. 2017;58:1499\u2013505.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1562_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/aos.13565","volume":"96","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96:120\u201333.","journal-title":"Acta Ophthalmol"},{"key":"1562_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.01.004","volume":"58","author":"MK Jones","year":"2017","unstructured":"Jones MK, Lu B, Girman S, Wang S. Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases. Prog Retin Eye Res. 2017;58:1\u201327.","journal-title":"Prog Retin Eye Res"},{"key":"1562_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/febs.14522","volume":"286","author":"H Kroeger","year":"2019","unstructured":"Kroeger H, Chiang WC, Felden J, Nguyen A, Lin JH. ER stress and unfolded protein response in ocular health and disease. FEBS J. 2019;286:399\u2013412.","journal-title":"FEBS J"},{"key":"1562_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep29025","volume":"6","author":"MA Gutierrez","year":"2016","unstructured":"Gutierrez MA, Davis SS, Rosko A, Nguyen SM, Mitchell KP, Mateen S, et al. A novel AhR ligand, 2AI, protects the retina from environmental stress. Sci Rep. 2016;6:29025.","journal-title":"Sci Rep"},{"key":"1562_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ophtha.2018.08.023","volume":"126","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, et al. Fight Retinal Blindness! Study Group. Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology. 2019;126:64\u201374.","journal-title":"Ophthalmology"},{"key":"1562_CR28","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","volume":"123","author":"RW Essex","year":"2016","unstructured":"Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH. et al. Fight Retinal Blindness Study Group. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393\u20132400.","journal-title":"Ophthalmology"},{"key":"1562_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","volume":"126","author":"CL Nguyen","year":"2019","unstructured":"Nguyen CL, Gillies MC, Nguyen V, Daien V, Cohn A, Banerjee G, et al. Fight Retinal Blindness! Study Group. Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Ophthalmology. 2019;126:735\u201342.","journal-title":"Ophthalmology"},{"key":"1562_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324.","journal-title":"Prog Retin Eye Res"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01562-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T04:06:06Z","timestamp":1648181166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01562-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JGG advises several pharmaceutical companies (Alcon, Allergan, Bayer and Novartis) and participates in a number of international, multicentre clinical studies in the fields of AMD and diabetic retinopathy that are sponsored by some of these companies (Chengdu Kanghong, Novartis and Bayer). These activities had no bearing on the study that gave rise to the submitted article for which JGG received neither direct nor indirect financial support; nor does he have any competing interests regarding the presented data. The other authors have no potential competing interests to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}